AKT1 and acute myeloid leukemia: On the other hand, MSCs derived from AML patients release CXCL8 which is a pro-inflammatory chemokine that can increase the proliferation and survival of AML blasts through the phosphoinositide-3-kinase (PI3K)/AKT pathway.